润都股份(002923.SZ)：硫酸氨基葡萄糖氯化钠复盐获得化学原料药上市申请批准

Core Viewpoint - The approval of the drug "Sodium Glucosamine Sulfate" by the National Medical Products Administration enhances the product portfolio of the company and is expected to positively impact its future operating performance [1] Group 1 - The company received a notice of approval for the drug, which is indicated for the treatment of primary and secondary osteoarthritis [1] - The approval is expected to enrich the company's product categories, thereby improving its market competitiveness [1] - The positive impact on the company's future operating performance is anticipated as a result of this approval [1]